PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9522035-7	1998	The intravenous injection of loxiglumide at 6, 18 and 60 mg/kg/h significantly inhibited an increase in total ascitic lipase activity, and plasma amylase and lipase activity of rats with closed duodenal loop.	loxiglumide	29-40	lipase G, endothelial type	Rattus norvegicus	118-124	
9522035-7	1998	The intravenous injection of loxiglumide at 6, 18 and 60 mg/kg/h significantly inhibited an increase in total ascitic lipase activity, and plasma amylase and lipase activity of rats with closed duodenal loop.	loxiglumide	29-40	lipase G, endothelial type	Rattus norvegicus	158-164	
7678322-5	1993	Loxiglumide pretreatment, in addition, significantly prevented the rise in serum amylase and lipase activity, as well as the increase in ascitic volume.	loxiglumide	0-11	lipase G, endothelial type	Rattus norvegicus	93-99	
7937691-5	1994	Low dose of loxiglumide significantly decreased pancreatic wet weight (-14%) and pancreatic contents of protein (-26%), trypsin (-38%), and lipase (-68%), while having no significant effect on pancreatic contents of DNA and amylase.	loxiglumide	12-23	lipase G, endothelial type	Rattus norvegicus	140-146	
7542770-5	1995	Loxiglumide treatment, although significantly decreasing protein output, had no influence on pancreatic weight, protein and DNA contents, or pancreatic juice flow but increased the amylase and lipase contents compared to those of the saline-treated postpancreatitic rats.	loxiglumide	0-11	lipase G, endothelial type	Rattus norvegicus	193-199	
7542770-7	1995	These results suggest that loxiglumide does not significantly inhibit the recovery of exocrine function but appears to accelerate the increase in pancreatic amylase and lipase contents even when given after an attack of acute pancreatitis.	loxiglumide	27-38	lipase G, endothelial type	Rattus norvegicus	169-175